Is preemptive therapy for CMV infection following liver transplantation superior to symptom-triggered treatment?

Transplant Proc. 2001 Feb-Mar;33(1-2):1804. doi: 10.1016/s0041-1345(00)02688-9.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Oral
  • Antigens, Viral / blood
  • Antiviral Agents / administration & dosage*
  • Biomarkers / blood
  • Case-Control Studies
  • Cytomegalovirus Infections / drug therapy
  • Cytomegalovirus Infections / immunology
  • Cytomegalovirus Infections / prevention & control*
  • Female
  • Ganciclovir / administration & dosage*
  • Humans
  • Liver Transplantation* / immunology
  • Male
  • Middle Aged
  • Phosphoproteins / blood
  • Prospective Studies
  • Viral Matrix Proteins / blood

Substances

  • Antigens, Viral
  • Antiviral Agents
  • Biomarkers
  • Phosphoproteins
  • Viral Matrix Proteins
  • cytomegalovirus matrix protein 65kDa
  • Ganciclovir